Acquired Company

Applied Therapeutics, Inc. has been acquired by Cycle Group Holdings Limited through a completed tender offer and merger, with stockholders receiving $0.088 in cash per share plus one contingent value right (CVR) per share.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. As of February 3, 2026, Applied Therapeutics, Inc. operates as a subsidiary of Cycle Group Holdings Limited. Show more

545 Fifth Avenue, New York, NY, 10017, United States

https://www.appliedtherapeutics.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

14.86M

52 Wk Range

$0.09 - $1.50

Previous Close

$0.10

Open

$0.10

Volume

N/A

Day Range

$0.10 - $0.10

Enterprise Value

5.418M

Cash

11.95M

Avg Qtr Burn

-18.4M

Insider Ownership

5.49%

Institutional Own.

68.78%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Govorestat (AT-007) Details Sorbitol dehydrogenase deficiency	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Govorestat (AT-007) Details Classic Galactosemia	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Caficrestat (AT-001) Details Hemophilia, Genetic disorder, Diabetic cardiomyopathy	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Govorestat (AT-007) Details Phosphomannomutase 2 deficiency , Congenital disorder of glycosylation	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AT-003 Details Diabetic retinopathy	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AT-104 Details Leukemia, B-cell acute lymphoblastic leukemia, T-cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.